Compare Amphastar Pharmaceuticals Inc (AMPH) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs General Motors Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while General Motors Company trades at $89.6 (market cap $76.85B). The key difference: General Motors Company is far larger — about 89× Amphastar Pharmaceuticals Inc's market cap, and General Motors Company pays a 0.82% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GM | |
|---|---|---|
Market Cap | $863.95M | $76.85B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $90.30 |
52-Week Low | $16.87 | $54.01 |
Enterprise Value | $1.26B | $179.83B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
General Motors (GM) trades at $87.58, up 0.74% today, showing strong technical momentum with a bullish moving average signal and support at $87. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.57 beating expectations of $3.19. Recent developments include the renewal of GM's China joint venture with SAIC for 20 years and expansion of EV charging infrastructure with Pilot and EVgo.
GM presents a compelling investment case with analyst consensus price target of $108.82 (24% upside), strong institutional support (65% buy ratings), and improving cash flow trends. However, risks include declining profit margins (1.05% net margin in 2025), rising debt levels, and competitive pressures in the EV transition. The stock offers value with attractive valuation multiples (P/S 0.44, P/B 1.24) but requires monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
